

# 2010 Cancer Data Summary

## Incidence of Cancer 2010

In 2010, 3,701 new cancer cases were accessioned into the NorthShore University HealthSystem Cancer Registry. Of those, 3,220 cases (87 percent) were analytic. By definition, analytic cases are those patients newly diagnosed with malignant neoplasm and/or have received all or part of their first course of treatment at one of our hospitals. The remaining 481 cases (13 percent) were non-analytic. Non-analytic cases are patients initially diagnosed and treated at another facility, who now are receiving treatment for progression or recurrence of their disease at NorthShore. **Details by site are provided in Table 1.**

## Class of Case 2010

Class of Case divides cases into two groups, analytic cases (Class 00-22) and non-analytic cases (Class 30-49).

Class 00-14, which account for 2,722 cases, were those malignancies diagnosed at one of our four hospitals. Once diagnosed with cancer, 2582 (95 percent) of our patients remained at NorthShore for their treatment. Class 20-22, totaling 498 cases, were diagnosed elsewhere and referred here for treatment. Class 30-38, a total of 481 cases, were diagnosed and treated elsewhere and referred here for treatment of a recurrence or progression of disease.

## Overall Top Five NorthShore Sites

Breast cancer continues to be our top site, representing a striking 24 percent of the total analytic cases seen at NorthShore. The next most frequent cancers seen were: lung (9 percent), prostate (7 percent), and colon and lymphoma (each, 5 percent). These top five sites represent 50 percent of all newly diagnosed cases.

## Distribution by AJCC Stage for the Top Five Sites Seen at NorthShore

Cancer diagnoses are classified into four of five stages depending on the site. Each stage represents how far the tumor has spread from the organ or site of origin, where an increasing value represents more tumor involvement or extension. Eighty-nine percent of our breast cancers were diagnosed at an early stage (Stages 0, I and II), reflecting the national (82 percent) trend toward early detection. Thirty-four percent of our lung cancers (national 27 percent), 83 percent of our prostate cancers (national 80 percent), 60 percent of our colon cancers (national 49 percent) and 49 percent of our lymphomas (national 36 percent) were also diagnosed with early stage disease. In each of the top sites seen at NorthShore, detection at an early stage was significantly higher or equal to that seen nationally. National data supplied by the 2011 *NCDB, Commission on Cancer, ACoS Benchmark Reports (2008 data)*, the latest year available. Data for NorthShore is from diagnosis year 2010. **See Table 2.**

## Overall Five-Year Survival for Top Five Sites

Stage at diagnosis also predicts the patient's survival rate or the percentage of people who will survive for five years after the cancer diagnosis. Survival calculations allow for the fact that some cancer patients die of other causes. Based on cases diagnosed in 1998–2002 and submitted to the National Cancer Data Base (NCDB), overall survival rates at NorthShore for the top five sites compare favorably to those seen nationally. For breast cancer, our overall five-year survival rate is 89 percent (national 85 percent). Longer or equivalent overall survival rates are seen for the remaining top four sites as well. For lung, 16 percent (national 14 percent); for prostate, 88 percent (national 86 percent); for colon, 58 percent (national 54 percent) and for lymphoma, 61 percent for NorthShore (national 60 percent). **See Graphs on pages 2, 6, 11, 12 and 17.**

Source: 2011 NCDB, Commission on Cancer, Survival Reports

**TABLE 1: INCIDENCE OF CANCER—  
2010 DATA SUMMARY**

Primary Site	Analytic	Non-Analytic	Total	Percent
<b>Oral Cavity and Pharynx</b>	<b>65</b>	<b>7</b>	<b>72</b>	<b>1.9%</b>
Tongue	23	2	25	
Salivary Glands	7	2	9	
Floor of Mouth	2	0	2	
Gum & Other Mouth	11	0	11	
Nasopharynx	1	1	2	
Tonsil	14	1	15	
Oropharynx	6	1	7	
Hypopharynx	1	0	1	
<b>Digestive System</b>	<b>489</b>	<b>72</b>	<b>561</b>	<b>15.2%</b>
Esophagus	27	4	31	
Stomach	50	12	62	
Small Intestine	18	1	19	
Colon Excluding Rectum	164	20	184	
Rectum & Rectosigmoid	72	9	81	
Anus, Anal Canal & Anorectum	8	0	8	
Liver & Intrahepatic Bile Duct	23	3	26	
Gallbladder	8	0	8	
Other Biliary	12	2	14	
Pancreas	99	17	116	
Retroperitoneum	2	3	5	
Peritoneum, Omentum & Mesentery	5	1	6	
Other Digestive Organs	1	0	1	
<b>Respiratory System</b>	<b>315</b>	<b>28</b>	<b>343</b>	<b>9.3%</b>
Nose, Nasal Cavity & Middle Ear	1	0	1	
Larynx	17	1	18	
Lung & Bronchus	295	26	321	
Pleura	0	1	1	
Trachea, Mediastinum & Other Respiratory Organs	2	0	2	
<b>Bones and Joints</b>	<b>3</b>	<b>1</b>	<b>4</b>	<b>0.1%</b>
<b>Soft Tissue</b>	<b>11</b>	<b>2</b>	<b>13</b>	<b>0.4%</b>
<b>Skin Excluding Basal and Squamous</b>	<b>105</b>	<b>22</b>	<b>127</b>	<b>3.4%</b>
Melanoma—Skin	99	20	119	
Other Non-Epithelial Skin	6	2	8	
<b>Breast</b>	<b>763</b>	<b>54</b>	<b>817</b>	<b>22.1%</b>
<b>Female Genital System</b>	<b>204</b>	<b>16</b>	<b>220</b>	<b>5.9%</b>
Cervix Uteri	15	0	15	
Corpus & Uterus, NOS	115	5	120	
Ovary	46	8	54	
Vagina	3	0	3	
Vulva	17	2	19	
Other Female Genital Organs	8	1	9	
<b>Male Genital System</b>	<b>257</b>	<b>85</b>	<b>342</b>	<b>9.2%</b>
Prostate	238	84	322	
Testis	18	0	18	
Penis	1	1	2	
<b>Urinary System</b>	<b>256</b>	<b>28</b>	<b>284</b>	<b>7.7%</b>
Urinary Bladder	140	20	160	
Kidney & Renal Pelvis	105	8	113	
Ureter	10	0	10	
Other Urinary Organs	1	0	1	
<b>Eye &amp; Orbit</b>	<b>18</b>	<b>3</b>	<b>21</b>	<b>0.6%</b>
<b>Brain &amp; Other Nervous System</b>	<b>155</b>	<b>71</b>	<b>226</b>	<b>6.1%</b>
Brain	64	38	102	
Cranial Nerves Other Nervous System	91	33	124	
<b>Endocrine System</b>	<b>228</b>	<b>36</b>	<b>264</b>	<b>7.1%</b>
Thyroid	153	14	167	
Other Endocrine Including Thymus	75	22	97	
<b>Lymphomas</b>	<b>154</b>	<b>16</b>	<b>170</b>	<b>4.6%</b>
Hodgkin Lymphoma	13	1	14	
Non-Hodgkin Lymphoma	141	15	156	
<b>Myeloma</b>	<b>32</b>	<b>8</b>	<b>40</b>	<b>1.1%</b>
<b>Leukemia</b>	<b>81</b>	<b>12</b>	<b>93</b>	<b>2.5%</b>
<b>Mesothelioma</b>	<b>9</b>	<b>1</b>	<b>10</b>	<b>0.3%</b>
<b>Kaposi Sarcoma</b>	<b>2</b>	<b>2</b>	<b>4</b>	<b>0.1%</b>
<b>Miscellaneous</b>	<b>73</b>	<b>17</b>	<b>90</b>	<b>2.4%</b>
<b>Total</b>	<b>3,220</b>	<b>481</b>	<b>3,701</b>	<b>100.0%</b>

**TABLE 2: STAGE OF DIAGNOSIS—  
2008/2010 DATA**

Comparison of National Cancer Data Base (NCDB) to NorthShore Data

Breast	NorthShore (n = 763) (%) 2010	NCDB (n = 202,083) (%) 2008*
<b>Stage</b>		
0	23.5%	20.3%
I	41.4%	37.7%
II	23.7%	24.4%
III	6.9%	8.7%
IV	3.6%	3.7%
NA	0.1%	0.1%
Unknown	0.5%	5.2%
<b>Total</b>	<b>100%</b>	<b>100%</b>

Lung	NorthShore (n = 295) (%) 2010	NCDB (n = 156,427) (%) 2008*
<b>Stage</b>		
0		0.2%
I	22.0%	21.7%
II	11.5%	5.6%
III	21.6%	23.3%
IV	42.3%	39.2%
OC		0.2%
NA		0.2%
Unknown	2.3%	9.7%
<b>Total</b>	<b>100%</b>	<b>100%</b>

Prostate	NorthShore (n = 238) (%) 2010	NCDB (n = 134,479) (%) 2008*
<b>Stage</b>		
0		0.0%
I	6.3%	1.0%
II	76.9%	79.2%
III	10.1%	8.3%
IV	6.3%	5.1%
NA	0.0%	0.0%
Unknown	0.4%	6.4%
<b>Total</b>	<b>100%</b>	<b>100%</b>

Colon	NorthShore (n = 164) (%) 2010	NCDB (n = 75,971) (%) 2008*
<b>Stage</b>		
0	15.8%	6.4%
I	23.1%	19.6%
II	21.3%	23.2%
III	21.3%	22.7%
IV	14.0%	18.0%
NA	0.0%	0.1%
Unknown	4.2%	9.8%
<b>Total</b>	<b>100%</b>	<b>100%</b>

Lymphoma	NorthShore (n = 154) (%) 2010	NCDB (n = 36,414) (%) 2008*
<b>Stage</b>		
I	30.5%	17.4%
II	18.8%	19.0%
III	19.4%	20.1%
IV	28.5%	31.3%
NA	0.6%	0.4%
Unknown	1.9%	11.9%
<b>Total</b>	<b>100%</b>	<b>100%</b>

Totals may not equal 100 due to rounding.  
Source: 2011 NCDB, Commission on Cancer  
\*2008 latest data available as of 8/30/2011